CR701

CR701 is a peripherally-acting cannabinoid receptor agonist developed by Cara Therapeutics for the treatment of chronic pain, specifically neuropathic pain. It is a small molecule designed to selectively modulate peripheral CB1 and CB2 cannabinoid receptors while minimizing central nervous system (CNS) exposure to avoid the psychotropic side effects typically associated with cannabinoid therapies. In preclinical rodent models, CR701 has demonstrated efficacy in reducing hyperalgesia and allodynia. The compound was developed as a potential non-opioid alternative for pain management, although its development has been secondary to the company's lead program, difelikefalin (CR845).